J Randall Patrinely Jr
Overview
Explore the profile of J Randall Patrinely Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goodman R, Garner D, Koester S, Patrinely Jr J, Dewan A, Johnson D
JAAD Int
. 2023 Jul;
12:139-141.
PMID: 37409320
No abstract available.
2.
Goodman R, Patrinely Jr J, Osterman T, Wheless L, Johnson D
Med
. 2023 Mar;
4(3):139-140.
PMID: 36905924
Goodman et al. discuss how AI technologies like the natural language processing model Chat-GPT could potentially transform healthcare through knowledge dissemination and personalized patient education. Before these tools can be...
3.
Creadore A, Desai S, Alloo A, Dewan A, Bakhtiar M, Cruz-Diaz C, et al.
JAMA Dermatol
. 2022 Jan;
158(2):176-183.
PMID: 34985493
Importance: Acute generalized exanthematous pustulosis (AGEP) is a rare, severe cutaneous adverse reaction associated with systemic complications. Currently available data are largely limited to small retrospective case series. Objective: To...
4.
Johnson D, Patrinely Jr J, Ye F
JAMA Oncol
. 2021 Aug;
7(10):1574-1575.
PMID: 34383022
No abstract available.
5.
Patrinely Jr J, Zakria D, Drolet B
Cutis
. 2021 Jul;
107(6):293-294.
PMID: 34314311
No abstract available.
6.
Brown L, Weppler A, Bhave P, Allayous C, Patrinely Jr J, Ott P, et al.
J Immunother Cancer
. 2021 May;
9(5).
PMID: 33963010
Background: Clinical trials of immunotherapy have excluded patients with pre-existing autoimmune disease. While the safety and efficacy of single agent ipilimumab and anti-PD1 antibodies in patients with autoimmune disease has...
7.
Patrinely Jr J, Walker S, Glassman G, Davis M, Abu-Ghname A, Khan U, et al.
Plast Reconstr Surg
. 2021 Apr;
147(5):1213-1218.
PMID: 33890907
Background: Financial key performance indicators are often used to evaluate performance. Understanding of key performance indicators can be crucial for career advancement and bargaining leverage in resource negotiations. This study...
8.
Patrinely Jr J, Johnson R, Lawless A, Bhave P, Sawyers A, Dimitrova M, et al.
JAMA Oncol
. 2021 Mar;
7(5):744-748.
PMID: 33764387
Importance: Agents targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and...
9.
Patrinely Jr J, McGuigan B, Chandra S, Fenton S, Chowdhary A, Kennedy L, et al.
Oncoimmunology
. 2021 Feb;
10(1):1875639.
PMID: 33628621
Immune checkpoint inhibitors (ICI) predispose patients to immune-related adverse events (irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not been well described. In this retrospective...
10.
Patrinely Jr J, Funck-Brentano E, Nguyen K, Rapisuwon S, Salem J, Gibney G, et al.
Oncologist
. 2020 Nov;
26(3):e505-e507.
PMID: 33225544
Background: The objective of this work was to characterize outcomes of patients with isolated brain metastases managed with local therapy followed by immune checkpoint inhibitor (ICI) therapy. Materials And Methods:...